Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia

被引:15
作者
Yang, Hwai-I [1 ,2 ,3 ]
Lee, Mei-Hsuan [4 ]
Liu, Jessica [1 ]
Chen, Chien-Jen [5 ]
机构
[1] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan
[2] China Med Univ, Grad Inst Clin Med Sci, Taichung 401, Taiwan
[3] China Med Univ Hosp, Mol & Genom Epidemiol Ctr, Taichung 401, Taiwan
[4] Natl Yang Ming Univ, Inst Clin Med, Taipei 115, Taiwan
[5] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol & Prevent Med, Taipei 115, Taiwan
关键词
Chronic hepatitis B; Hepatocellular carcinoma; Risk calculator; Hepatitis B virus; GENOME-WIDE ASSOCIATION; SCORING SYSTEM; INFECTION; GENOTYPE; THERAPY; ANTIGEN; SCORES; LOCUS; DNA;
D O I
10.3748/wjg.v20.i20.6244
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Risk calculators are widely used in many clinical fields, and integrate several important risk factors through the conversion of a risk function into a single measure of risk. Several studies have been carried out to create risk calculators for the prediction of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Most of them were hospital-based, with limited sample sizes and insufficient external validation. These study groups collaborated to establish the REACH-B risk score, which incorporated five clinical variables to predict HCC risk. This risk score was then validated in international clinical cohorts. Evidence suggests that quantitative serum HBsAg level provides additional predictability of HCC, especially in patients with low levels of hepatitis B virus DNA. This novel marker was incorporated into a risk calculator and was internally validated. This tool will hopefully be externally validated in the near future. Risk calculators can be used to support clinical practice, and to establish preventive measures; several "off-label" extension usages have also been implemented. Albeit beneficial, several precautions and discussions should be noted in using the risk calculators. The future development of risk calculators for CHB patients can be extended by applying them to additional CHB-related outcomes, and by incorporating emerging risk parameters. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:6244 / 6251
页数:8
相关论文
共 29 条
  • [1] Epidemiological characteristics and risk factors of hepatocellular carcinoma
    Chen, CJ
    Yu, MW
    Liaw, YF
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1997, 12 (9-10) : S294 - S308
  • [2] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chen, CJ
    Yang, HI
    Su, J
    Jen, CL
    You, SL
    Lu, SN
    Huang, GT
    Iloeje, UH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01): : 65 - 73
  • [3] Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients
    Chen, T. -M.
    Chang, C. -C.
    Huang, P. -T.
    Wen, C. -F.
    Lin, C. -C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) : 243 - 251
  • [4] How to predict HCC development in patients with chronic B viral liver disease?
    Han, KH
    Ahn, SH
    [J]. INTERVIROLOGY, 2005, 48 (01) : 23 - 28
  • [5] Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma
    Jiang, De-Ke
    Sun, Jielin
    Cao, Guangwen
    Liu, Yao
    Lin, Dongxin
    Gao, Yu-Zhen
    Ren, Wei-Hua
    Long, Xi-Dai
    Zhang, Hongxing
    Ma, Xiao-Pin
    Wang, Zhong
    Jiang, Wei
    Chen, Tao-Yang
    Gao, Yong
    Sun, Liang-Dan
    Long, Ji-Rong
    Huang, Hui-Xing
    Wang, Dan
    Yu, Hongjie
    Zhang, Pengyin
    Tang, Li-Sha
    Peng, Bo
    Cai, Hao
    Liu, Ting-Ting
    Zhou, Ping
    Liu, Fang
    Lin, Xiaoling
    Tao, Sha
    Wan, Bo
    Sai-Yin, He-Xi Ge
    Qin, Lun-Xiu
    Yin, Jianhua
    Liu, Li
    Wu, Chen
    Pei, Yan
    Zhou, Yuan-Feng
    Zhai, Yun
    Lu, Pei-Xin
    Tan, Aihua
    Zuo, Xian-Bo
    Fan, Jia
    Chang, Jiang
    Gu, Xiaoli
    Wang, Neng-Jin
    Li, Yang
    Liu, Yin-Kun
    Zhai, Kan
    Zhang, Hongwei
    Hu, Zhibin
    Liu, Jun
    [J]. NATURE GENETICS, 2013, 45 (01) : 72 - U105
  • [6] Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
    Kao, JH
    Chen, PJ
    Lai, MY
    Chen, DS
    [J]. GASTROENTEROLOGY, 2000, 118 (03) : 554 - 559
  • [7] Risk score for development of HCC: ready for use in practice?
    Keeffe, Emmet B.
    [J]. LANCET ONCOLOGY, 2011, 12 (06) : 517 - 518
  • [8] LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA
    Kim, W. R.
    Berg, T.
    Loomba, R.
    Schall, R. Aguilar
    Dinh, P.
    Yee, L. J.
    Martins, E. B.
    Flaherty, J. F.
    Gurel, S.
    Buti, M.
    Marcellin, P.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S19 - S19
  • [9] Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
    Lavanchy, D
    [J]. JOURNAL OF VIRAL HEPATITIS, 2004, 11 (02) : 97 - 107
  • [10] Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles
    Lee, Mei-Hsuan
    Yang, Hwai-I.
    Liu, Jessica
    Batrla-Utermann, Richard
    Jen, Chin-Lan
    Iloeje, Uchenna H.
    Lu, Sheng-Nan
    You, San-Lin
    Wang, Li-Yu
    Chen, Chien-Jen
    [J]. HEPATOLOGY, 2013, 58 (02) : 546 - 554